XML 21 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net income/(loss) $ 13,453,901 $ (4,186,799)
Adjustments to reconcile net income/(loss) to net cash used in operating activities:    
Depreciation and other amortization 407,692 400,702
Stock-based compensation 2,876,071 1,589,993
Write down of inventory, net 327,373 562,941
Deferred income taxes, net (1,056,647) (1,647,191)
Deferred IV TPOXX® revenue (7,059,280) 10,240,000
Changes in assets and liabilities:    
Accounts receivable 9,041,941 37,356,901
Inventory 2,676,093 (26,240,079)
Prepaid expenses and other assets (2,992,590) (1,433,011)
Accounts payable, accrued expenses and other liabilities (3,659,762) 379,384
Income tax payable (21,563,085) (1,255,240)
Net cash (used in)/provided by operating activities (7,548,293) 15,767,601
Cash flows from investing activities:    
Capital expenditures (24,612) (21,686)
Cash used in investing activities (24,612) (21,686)
Cash flows from financing activities:    
Payment of employee tax obligations for common stock tendered (638,139) (214,794)
Repurchase of common stock 0 (11,072,511)
Payment of dividend (42,665,044) (32,135,118)
Cash used in financing activities (43,303,183) (43,422,423)
Net decrease in cash and cash equivalents (50,876,088) (27,676,508)
Cash and cash equivalents at the beginning of period 150,145,844 98,790,622
Cash and cash equivalents at end of period 99,269,756 71,114,114
Supplemental disclosure of non-cash financing activities:    
Non-cash lease right-of-use asset and associated liability 462,686 0
Issuance of common stock 417,000 0
Issuance of common stock upon cashless exercise $ 0 $ 87,540